Results
- Showing results for:
- Reset all filters
Search results
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
OtherCheng Z, Mirza H, Ennis DP, et al., 2023,
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
<jats:p>Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma</jats:p>
-
Journal articleSupramaniam P, Wang Z, Chatzimichail S, et al., 2023,
Measuring encapsulation efficiency in cell-mimicking giant unilamellar vesicles
, ACS Synthetic Biology, Vol: 12, Pages: 1227-1238, ISSN: 2161-5063One of the main drivers within the field of bottom-up synthetic biology is to develop artificial chemical machines, perhaps even living systems, that have programmable functionality. Numerous toolkits exist to generate giant unilamellar vesicle-based artificial cells. However, methods able to quantitatively measure their molecular constituents upon formation is an underdeveloped area. We report an artificial cell quality control (AC/QC) protocol using a microfluidic-based single-molecule approach, enabling the absolute quantification of encapsulated biomolecules. While the measured average encapsulation efficiency was 11.4 ± 6.8%, the AC/QC method allowed us to determine encapsulation efficiencies per vesicle, which varied significantly from 2.4 to 41%. We show that it is possible to achieve a desired concentration of biomolecule within each vesicle by commensurate compensation of its concentration in the seed emulsion. However, the variability in encapsulation efficiency suggests caution is necessary when using such vesicles as simplified biological models or standards.
-
Journal articleScarpone R, Kimkool P, Ierodiakonou D, et al., 2023,
Timing of allergenic food introduction and risk of IgE-mediated food allergy: systematic review and meta-analysis
, JAMA Pediatrics, Vol: 177, Pages: 489-497, ISSN: 1072-4710Importance Earlier egg and peanut introduction probably reduces risk of egg and peanut allergy, respectively, but it is uncertain whether food allergy as a whole can be prevented using earlier allergenic food introduction.Objective To investigate associations between timing of allergenic food introduction to the infant diet and risk of food allergy.Data Sources In this systematic review and meta-analysis, Medline, Embase, and CENTRAL databases were searched for articles from database inception to December 29, 2022. Search terms included infant, randomized controlled trial, and terms for common allergenic foods and allergic outcomes.Study Selection Randomized clinical trials evaluating age at allergenic food introduction (milk, egg, fish, shellfish, tree nuts, wheat, peanuts, and soya) during infancy and immunoglobulin E (IgE)–mediated food allergy from 1 to 5 years of age were included. Screening was conducted independently by multiple authors.Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline was used. Data were extracted in duplicate and synthesized using a random-effects model. The Grading of Recommendations, Assessment, Development, and Evaluation framework was used to assess certainty of evidence.Main Outcomes and Measures Primary outcomes were risk of IgE-mediated allergy to any food from 1 to 5 years of age and withdrawal from the intervention. Secondary outcomes included allergy to specific foods.Results Of 9283 titles screened, data were extracted from 23 eligible trials (56 articles, 13 794 randomized participants). There was moderate-certainty evidence from 4 trials (3295 participants) that introduction of multiple allergenic foods from 2 to 12 months of age (median age, 3-4 months) was associated with reduced risk of food allergy (risk ratio [RR], 0.49; 95% CI, 0.33-0.74; I2 = 49%). Absolute risk difference for a population with 5% incidence of food allergy was −
-
Journal articleNuh A, Ramadan N, Nwankwo L, et al., 2023,
COVID-19 associated pulmonary aspergillosis in patients on extracorporeal membrane oxygenation treatment-a retrospective study
, Journal of Fungi, Vol: 9, ISSN: 2309-608XBACKGROUND: The incidence and outcome of pulmonary aspergillosis in coronavirus disease (COVID-19) patients on extracorporeal membrane oxygenation (ECMO) are unknown and have not been fully addressed. We investigated the incidence, risk factors and outcome of pulmonary aspergillosis in COVID-19 ECMO patients. In addition, the diagnostic utility of bronchoalveolar lavage fluid and CT scans in this setting were assessed. METHODS: We conducted a retrospective study on incidence and outcome of pulmonary aspergillosis in COVID-19 ECMO patients by reviewing clinical, radiological, and mycological evidence. These patients were admitted to a tertiary cardiothoracic centre during the early COVID-19 surge between March 2020 and January 2021. Results and measurements: The study included 88 predominantly male COVID-19 ECMO patients with a median age and a BMI of 48 years and 32 kg/m2, respectively. Pulmonary aspergillosis incidence was 10% and was associated with very high mortality. Patients with an Aspergillus infection were almost eight times more likely to die compared with those without infection in multivariate analysis (OR 7.81, 95% CI: 1.20-50.68). BALF GM correlated well with culture results, with a Kappa value of 0.8 (95% CI: 0.6, 1.0). However, serum galactomannan (GM) and serum (1-3)-β-D-glucan (BDG) lacked sensitivity. Thoracic computed tomography (CT) diagnostic utility was also inconclusive, showing nonspecific ground glass opacities in almost all patients. CONCLUSIONS: In COVID-19 ECMO patients, pulmonary aspergillosis incidence was 10% and associated with very high mortality. Our results support the role of BALF in the diagnosis of pulmonary aspergillosis in COVID-19 ECMO patients. However, the diagnostic utility of BDG, serum GM, and CT scans is unclear.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.